FilingReader Intelligence

Haisco Pharmaceutical gains approval for innovative drug trial

July 1, 2025 at 05:12 PM UTCBy FilingReader AI

Haisco Pharmaceutical Group (SZSE:002653) announced that its subsidiary, Tibet Haisco Pharmaceutical, has received approval from the National Medical Products Administration (NMPA) to begin clinical trials for its innovative drug, HSK45030 dispersible tablets. The drug, classified as a Category 1 chemical drug, is designed as a selective small molecule inhibitor for the treatment of muscular dystrophy. Preclinical studies have demonstrated HSK45030's efficacy in preventing muscle function loss and reducing fibrosis and fat accumulation caused by contraction-induced damage. The company believes HSK45030 holds significant potential and could offer a new therapeutic option for patients suffering from muscular dystrophy. While the approval marks a positive step, Haisco Pharmaceutical cautions investors about the inherent risks associated with drug development and pledges to provide timely updates on the project's progress.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Haisco Pharmaceutical Group publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →